ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO
→ ADC Therapeutics, which last month closed its monster $303 million E round, is joining forces with Freenome, a biotech developing a diagnostic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
